You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis
Contributor:
Miccoli, Mario;
Bertelloni, Silvano;
Massart, Francesco
Published:
S. Karger AG, 2016
Published in:
Hormone Research in Paediatrics, 86 (2016) 1, Seite 27-34
Language:
English
DOI:
10.1159/000446958
ISSN:
1663-2818;
1663-2826
Origination:
Footnote:
Description:
<b><i>Background/Aims:</i></b> Although recombinant human growth hormone (rhGH) is not approved to treat short stature of achondroplasia (ACH), some studies suggested growth improvement during short-term rhGH treatment. <b><i>Methods:</i></b> A meta-analysis of rhGH therapy efficacy in ACH children was performed. <b><i>Results:</i></b> From 12 English-language studies, 558 (54.0% males) rhGH-treated ACH children were enrolled. Administration of rhGH (median dosage 0.21 mg/kg/ week; range 0.16-0.42 mg/kg/week) improved height (Ht) from baseline [-5.069 standard deviation score (SDS; 95% CI -5.109 to -5.029); p < 0.0001] to 12 [-4.325 SDS (95% CI -4.363 to -4.287); p < 0.0001] and 24 months [-4.073 SDS (95% CI -4.128 to -4.019); p < 0.0001]. Then, Ht remained approximately constant up to 5 years [-3.941 SDS (95% CI -4.671 to -3.212); p < 0.0001]. <b><i>Conclusions:</i></b> In ACH children, rhGH treatment increased Ht from -5.0 to -4.0 SDS during 5 years, but insufficient data are available on both the adult Ht and the changes of body proportions.